Actelion Ltd today announced the approval of Opsumit (macitentan) for the treatment of pulmonary arterial hypertension (PAH) by the Therapeutic Goods Administration.
Opsumit, as monotherapy or in combination with approved PAH treatments (phosphodiesterase-5 inhibitors or inhaled prostanoids), is indicated for the treatment of idiopathic and heritable PAH as well as PAH associated with connective tissue disease and PAH associated with congenital heart disease with repaired shunts in patients with WHO Functional class II, III or IV symptoms.

The PBAC will consider a submission to list Opsumit on the PBS when it meets next month.
For more details, go to: http://www.actelion.com/en/our-company/news-and-events/index.page?newsId=1759905